A new type of topical brimonidine gel
By using natural volatile oils instead of methylparaben in brimonidine gel, the side effects and crystallization problems of methylparaben were resolved, improving the treatment effect on rosacea, especially reducing erythema and papules and promoting wound healing.
Patent Information
- Application Number
- CN202310188180.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-01
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-03-01
AI Technical Summary
The methylparaben preservative in existing brimonidine gels poses risks of side effects and crystallization problems, and its treatment effect on papular and pustular rosacea is not good.
Natural volatile oils such as tea tree oil and lavender oil are used as preservatives to replace methylparaben, and combined with brimonidine tartrate, gelling agents, moisturizers, physical sunscreens and pH adjusters to form a topical gel.
It significantly reduces the side effects of methylparaben, improves the treatment effect on erythema and papules, promotes wound healing, and reduces skin irritation. It is suitable for the treatment of mild to moderate erythematous rosacea and papulopustular rosacea.
Smart Images

Figure CN116159018B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medical technology, and in particular to a novel external brimonidine gel containing volatile oil, a preparation method thereof, and application thereof in treating mild and moderate erythematous vascular dilation type and papulopustular rosacea. Background Art
[0002] Brimonidine tartrate is 5-bromo-6-(2-imidazole diene amino)quinoxaline L-tartrate, and its structural formula is as follows:
[0003]
[0004] As an adrenergic α2-receptor agonist, it acts on the iris-ciliary α2-adrenergic receptors, reduces the production of aqueous humor, and thus reduces intraocular pressure with minimal side effects. 0.2% is used clinically and 0.15% Brimonidine tartrate eye drops are used to treat open-angle glaucoma and ocular hypertension. In recent years, studies have found that brimonidine has the physiological effect of constricting blood vessels. In 2013, the FDA approved Galderma's new product. It is a topical gel with a concentration of 0.33% brimonidine (equivalent to 5% brimonidine tartrate). It acts on the smooth muscles around the facial blood vessels to constrict the blood vessels, thereby alleviating symptoms such as facial erythema and edema. It is mainly suitable for erythematous vascular dilation type rosacea. Rosacea is a chronic inflammatory skin disease that often occurs in the middle of the face and mainly affects the subcutaneous blood vessels and hair follicles and sebaceous glands of the face. It is mainly characterized by facial red patches, capillary dilation, papules, edema and other symptoms, usually accompanied by burning, stinging, itching and other symptoms. At present, its cause and pathogenesis are not clear. It is mainly believed to be related to factors such as immune system defects, abnormal neurovascular vasomotor function and local microbial infection. At the same time, it is affected by external factors such as ultraviolet rays, temperature stimulation, diet, and emotions. Rosacea is difficult to cure. The main purpose of current clinical treatment is to alleviate clinical symptoms and slow down the progression of the disease. For patients with mild to moderate rosacea, topical medications are often used for treatment. Brimonidine gel has the advantages of rapid effect, low side effects, and easy use, but it has no obvious effect on papules, pustules and the skin damage caused by them (Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017; 31(11): 1775-91).
[0005] Gels refer to thick liquid or semisolid preparations made of drugs and excipients that can form gels, such as solutions, suspensions or emulsions. The composition of the gel prescription mainly includes drugs, carbomer, propylene glycol and glycerol, methylparaben or methylparaben, titanium dioxide, pH regulator, and water. The currently disclosed patent for brimonidine topical gel is mainly CN2011800508992 of Galderma Company, which discloses a brimonidine gel with methylparaben as the main preservative for treating mild and moderate erythematous rosacea. The patent mainly solves the problem of preventing microbial contamination of methylparaben crystals in the gel, but the water solubility of solid methylparaben is low and the crystallinity is affected by the concentration of carbomer. After the gel is opened and used, there is still a risk of crystallization. In addition, although methylparaben has been widely used as a preservative for oral and topical preparations, recent studies have shown that long-term repeated use of methylparaben preservatives still has many potential risks. In a skin toxicity study conducted by CTFA, a product formula containing 0.2% methylparaben was topically applied to albino rabbits for 3 months, receiving a daily dose of 5.5 mg / cm2, applied to 8.4% of the body surface area. The results showed that compared with the control group, the product containing methylparaben can cause persistent significant to moderate erythema, mild edema and intermittent mild desquamation (CTFA, 1981b. Subchronic (three-month) dermal toxicity study in rabbit with product CN0028 containing methyl paraben.). It is particularly noteworthy that Darbre, P et al. also found that methylparaben has a very strong estrogenic activity on MCF7 breast cancer cells, which may reach several thousand times that of 17-β-estradiol, indicating that the large-scale use of preparations added with methylparaben will increase the risk of breast cancer in women. William H et al. also found that the addition of methylparaben can increase the drug resistance of breast cancer cells and hinder the chemotherapy process of patients, further exacerbating the public's concerns about the large-scale use of methylparaben (Goodson WHet al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733).
[0006] Essential Oils refers to the general term for volatile oily aromatic substances extracted from spice plants. Natural plant essential oils are safe and non-toxic, and have the effects of sterilization, anti-inflammatory, healing, deodorization, sedation, insect repellent, and soft and delicate skin. Essential oils are not only widely used in topical medicines and cosmetics, but also have a long history. Commonly used essential oils with good antibacterial activity include tea tree oil, lavender oil, wormwood oil, orange blossom oil, lemon oil, geranium oil, etc. Tea tree oil is a natural plant essential oil distilled from the leaves of the Australian native plant Melaleuca alternifolia. It is a colorless to light yellow liquid with a characteristic aroma. The main components are 1.8-cineole, α-terpinene and γ-terpinene. γ-terpinene has been shown to affect the formation of bacterial cell walls, destroy the cytoplasmic membrane, and inhibit glucose-dependent respiration, so it plays a unique role in antibacterial and anti-inflammatory. Carson CF et al. found that its MIC against Staphylococcus aureus 90 0.5% (Carson CF, Hammer KA, Riley TV. Broth micro-dilution method for determining the susceptibility of Escherichia coli and Staphylococcus aureus to the essential oil of Melaleuca alternifolia (tea tree oil). Microbios 1995; 82: 181-5), Banes-Marshall L et al. found that its MIC against Pseudomonas aeruginosa 90Less than 2% (Banes-Marshall L, Cawley P, Phillips CA. In vitro activity of Melaleuca alternifolia (tea tree) oil against bacteria and Candida spp. isolates from clinical specimens. Br J Biomed Sci 2001; 58: 139-45.), all indicating that it has a good inhibitory effect on common pathogenic microorganisms and has the potential to be a natural preservative. At the same time, it has also been studied in promoting wound healing. Kerr J et al., in a study of 100 patients with chronic wounds, showed that the wound healing speed of topical tea tree oil mixed preparations as an adjuvant treatment exceeded expectations, and at the same time, inflammation, pain and bad wound odor were also rapidly reduced (Kerr J. using essential oils in wound care for the elderly. Aromatherapy Today 2002; 23: 14-9.). In addition, the drug toxicity studies on tea tree oil have shown that it has good safety and has no irritation or side effects on the skin as an external preparation. The studies of Saller R, Berger T, Reichling J et al. have shown that the acute dermal LD of tea tree oil can be studied using an albino rabbit model. 50 When the data was collected, 5.0g / kg.BW 100% tea tree oil was applied to the skin of albino rabbits and maintained at 2g / kg.BW for 24h. The experimental subjects showed no signs of toxicity. A 30-day skin irritation test using 25% paraffin tea tree oil ointment on the skin of ordinary rabbits did not produce obvious irritation (Saller R, Berger T, Reichling J, et al. Pharmaceutical and medicinal aspects of Australian tea tree oil. Phytomedicine 1998; 5: 489-95.). The LD50 of methylparaben in rat dermis is about 500-1200mg / kg.BW, which is much more toxic than tea tree oil. Lavender oil, wormwood oil, orange flower oil, lemon oil, geranium oil, etc. also have significant inhibitory effects on Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans.
[0007] In view of the above-mentioned risk problems caused by the methylparaben preservative in brimonidine gel, this patent provides a topical brimonidine tartrate gel containing antibacterial volatile oil and methylparaben-free, and its application in the treatment of mild and moderate erythematous vasodilatory and papulopustular rosacea. The research results are gratifying in that the volatile oil can significantly increase the efficacy of brimonidine tartrate in relieving the area and symptoms of erythema and papules in patients with rosacea, and has good application prospects. Summary of the invention
[0008] The invention aims to provide a topical brimonidine tartrate gel containing antibacterial volatile oil and free of methylparaben, and its application in treating mild and moderate erythematous vasodilatory and papulopustular rosacea.
[0009] The topical brimonidine gel is composed of the following materials in parts by weight: brimonidine tartrate, 0.03-6.6% (w / w), volatile oil 1-30% (w / w), gelling agent 0.5-2% (w / w), moisturizing agent 4.5-15% (w / w), physical sunscreen 0.05-0.5% (w / w), pH regulator 0.5-2.5%, purified water 46-90%. As a preferred embodiment of the present invention, the following materials are included in a weight ratio: brimonidine tartrate: volatile oil: gelling agent: moisturizing agent: physical sunscreen: pH regulator: purified water = (0.2-0.8%): (5-20%): (0.8-1.5%): (7-12%): (0.05-0.1%): (0.5-1%): (65-86%).
[0010] The pH of the topical brimonidine gel is 5.5-8.0, and the pH is preferably 6.5-7.5. The pH detection method is: take 0.5g of the sample, add 25ml of distilled water and anhydrous methanol respectively, stir to fully dissolve it, and then use a pH agent to measure it.
[0011] In the topical brimonidine gel, the volatile oil is an extract obtained by extraction and purification from natural plants and having antibacterial activity. The volatile oil is selected from one or more of lavender oil, tea tree oil, wormwood oil, orange blossom oil, lemon oil, and geranium oil; as a preferred embodiment of the present invention, the volatile oil is preferably tea tree oil. Further preferred embodiments of the present invention are that the amount of tea tree oil added is 10%.
[0012] In the topical brimonidine gel, the gelling agent is selected from one or more of carbomer 934P, carbomer 940, carbomer 941, carbomer 974P, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl cellulose, preferably carbomer 974P; the moisturizing agent is selected from one or more of propylene glycol, glycerol, butylene glycol, polyethylene glycol, polypropylene glycol, and sorbitol; the physical sunscreen is selected from one or more of titanium dioxide, nano titanium dioxide, zinc oxide, and nano zinc oxide; and the pH regulator is selected from one or more of sodium hydroxide, potassium hydroxide, and triethanolamine, preferably sodium hydroxide.
[0013] The topical brimonidine gel is specifically prepared as follows: accurately weigh the prescribed amount of gelling agent, add an appropriate amount of pure water, and swell for 12 hours for standby use. Accurately weigh the prescribed amount of brimonidine tartrate, volatile oil, moisturizer, and physical sunscreen, add them to the swollen carbomer solution, stir at 500r / min for 15min until the mixture is completely mixed, then increase the speed to 800r / min, adjust the mixture to a suitable pH with 1.5M sodium hydroxide solution, finally add an appropriate amount of pure water until sufficient, and continue stirring until the finished product is a light yellow-green uniform gel.
[0014] The topical brimonidine gel is characterized by being suitable for topical administration and treating, but not limited to, mild and moderate erythematous vascular dilation type and papulopustular rosacea.
[0015] The beneficial effects of the new topical brimonidine gel: (1) Volatile oil is used instead of methyl paraben as the antibacterial agent of the preparation, avoiding the side effects related to methyl paraben preservatives and the risk of crystallization during storage and use. (2) Volatile oil can significantly increase the efficacy of brimonidine in relieving the symptoms of erythema and papules in patients with rosacea. (3) Volatile oil has bactericidal and anti-inflammatory effects on the skin, which helps to make up for the shortcomings of brimonidine gel preparations in dealing with rosacea caused by bacterial and trichophyton infection; volatile oil can promote wound healing and is beneficial for the treatment of pustules, papules and other symptoms caused by rosacea. (4) Volatile oils such as tea tree oil are natural plant extracts that can further reduce the irritation of the preparation to the skin and have high safety. (5) The prescription process is simple, the cost is low, and it is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The effect of gelling agent concentration on the in vitro release of brimonidine gel.
[0017] Figure 2 The effect of combined moisturizer concentration on the in vitro release of brimonidine gel.
[0018] Figure 3 Comparison of in vitro release profiles of brimonidine gel with and without tea tree oil.
[0019] Figure 4 Comparison of reduction in erythema area after treatment with brimonidine gel containing tea tree oil (*P<0.05, **P<0.01)
[0020] Figure 5 Efficacy score of brimonidine gel containing tea tree oil (*P<0.05, **P<0.01) DETAILED DESCRIPTION
[0021] The present application is described in detail below with reference to specific examples. The drugs, reagents, animals, etc. mentioned in the examples are all commercially available products.
[0022] Example 1 Preparation of brimonidine gels with different concentrations of gelling agents.
[0023] Accurately weigh 0.5g, 1.0g, and 1.5g of Carbomer 974P respectively, add about 60ml of pure water, and swell for 12h for use; add 0.5g of brimonidine tartrate, 0.05g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol to each group, stir at 500r / min for 15min until mixed completely, then increase the speed to 800r / min, add 1.5M sodium hydroxide solution dropwise to pH=7, and finally add appropriate amount of pure water to make up the total weight of the sample to 100g.
[0024] Example 2 Brimonidine gels with different concentrations of moisturizer combinations (glycerol, propylene glycol) were prepared.
[0025] Accurately weigh 1.0g of Carbomer 974P, add about 60ml of pure water, and swell for 12h for use; accurately weigh 0.5g of brimonidine tartrate and 0.05g of titanium dioxide, and add a low-concentration moisturizer combination (3.5g of glycerol and 3.5g of propylene glycol), a medium-concentration moisturizer combination (5.0g of glycerol and 5.0g of propylene glycol) and a high-concentration moisturizer combination (6.5g of glycerol and 6.5g of propylene glycol) to the swollen Carbomer solution, stir at 500r / min for 15min until the mixture is completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution to pH=7, and finally add an appropriate amount of pure water to make up the total weight of the sample to 100g.
[0026] Example 3 Preparation of brimonidine gel.
[0027] Accurately weigh 1.0g of Carbomer 974P, add about 60ml of pure water, and swell for 12h for use; accurately weigh 0.5g of brimonidine tartrate, 0.05g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol, add them to the swollen Carbomer solution, stir at 500r / min for 15min until completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution to pH=7, and finally add appropriate amount of pure water to make up the total weight of the sample to 100g.
[0028] Example 4 Preparation of brimonidine gel with different concentrations of tea tree oil
[0029] Accurately weigh 1.0g of carbomer 974P, add about 60ml of pure water, and swell for 12h for use; add 0.5g of brimonidine tartrate, 0.05g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol, weigh 1g, 5g, 10g, 20g, and 30g of tea tree oil respectively, add them to the carbomer solution, stir at 500r / min for 15min until completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution to pH=7, and finally add appropriate amount of pure water to make up the total weight of the sample to 100g.
[0030] Example 5 Preparation of tea tree oil gels of different concentrations.
[0031] Accurately weigh 1.0g of Carbomer 974P, add about 60ml of pure water, and swell for 12h for use; add 0.05g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol, weigh 5g, 10g, and 20g of tea tree oil respectively, add them to the Carbomer solution, stir at 500r / min for 15min until completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution to pH = 7, and finally add appropriate amount of pure water to make up the total weight of the sample to 100g.
[0032] Example 6 Preparation of brimonidine tartrate gel containing wormwood oil.
[0033] Weigh 1.0g of Carbomer 940 accurately, add about 60ml of pure water, and swell for 12h for later use; weigh 0.6g of brimonidine tartrate, 10g of wormwood oil, 0.08g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol accurately, add them to the swollen Carbomer solution, stir at 500r / min for 15min until the mixture is completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution until the pH is 6.90, and finally add an appropriate amount of pure water to make up the total weight of the sample to 100g.
[0034] Example 7 Preparation of brimonidine tartrate gel containing lavender oil.
[0035] Accurately weigh 1.0g of Carbomer 940, add about 60ml of pure water, and swell for 12h for use; accurately weigh 0.7g of brimonidine tartrate, 15g of lavender oil, 0.1g of titanium dioxide, 5g of glycerol, and 5g of propylene glycol, add them to the swollen Carbomer solution, stir at 500r / min for 15min until completely mixed, then increase the speed to 800r / min, slowly drip 1.5M sodium hydroxide solution to pH = 7.18, and finally add appropriate amount of pure water to make up the total weight of the sample to 100g.
[0036] Example 8 In vitro release test of drug gel
[0037] The Franz three-dimensional diffusion cell was used as the gel drug release device, and the effective diffusion area was about 0.786 cm2. A 0.45 μm PVDF microporous filter membrane was selected as the permeable membrane. After the diffusion cell was installed, the receiving cell was filled with PBS buffer solution (pH = 7.4), and 1 ml of gel sample was added to the dosing cell to ensure that there was no bubble retention between the receiving cell and the dosing cell. The device was placed on a magnetic stirrer and connected to 32°C constant temperature circulating water. 1 ml of the receiving solution was taken out at 30 min, 1 h, 2 h, 4 h, 6 h, 12 h, and 24 h (while supplemented with 1 ml of isothermal PBS buffer), and the filtrate was filtered and analyzed by HPLC to determine the concentration of brimonidine and calculate the cumulative release amount.
[0038] (1) To investigate the effect of the dosage of gelling agent on brimonidine gel.
[0039] The brimonidine gel of different concentrations of gelling agent in Example 1 was subjected to the above in vitro release test. The results are shown in Figure 1 . Figure 1 It shows that low concentration gelling agent has the best release rate, but the sample prepared at a concentration of 0.5% is a viscous liquid, and its viscosity is only 72cP, which does not meet the gel requirement. Therefore, the gelling agent is selected at a concentration of 1.0%, and its sample viscosity is 1200cP, which meets the gel requirement.
[0040] (2) To investigate the effect of moisturizer dosage on brimonidine gel.
[0041] The samples prepared in Example 2 were used as experimental subjects to conduct the above-mentioned in vitro release test. Figure 2 , Figure 2 It can be seen that the gel prepared with a medium concentration moisturizer combination (5 g glycerol, 5 g propylene glycol) has the best release performance, so the moisturizer combination in the gel is selected as 5 g glycerol and 5 g propylene glycol.
[0042] (3) To compare the in vitro release of brimonidine gel with and without tea tree oil.
[0043] The release test was carried out on the brimonidine gel with a tea tree oil concentration of 10% in Examples 3 and 4. The results are shown in Figure 3 , Figure 3 It showed that the addition of tea tree oil was beneficial to the release of brimonidine from the gel.
[0044] Example 9 Preliminary study on the compatibility of brimonidine gel containing tea tree oil
[0045] 10 g of brimonidine tartrate gel containing 10% tea tree oil in Example 4 was placed in an aluminum-plastic tube package, sealed and placed in a 40°C constant temperature stabilization box, and samples were taken on the 0th, 5th and 10th days to measure the brimonidine concentration and observe the appearance. The results are shown in Table 1. Table 1 Compatibility test results of brimonidine tartrate gel containing tea tree oil (10%) (n=3)
[0046] Time / d Appearance Weight / g pH content% Appearance 0 Yellow-green uniform gel 10.03±0.02 6.99±0.04 0.491±0.21 Uniform, no crystallization 5 Yellow-green uniform gel 9.81±0.04 7.03±0.08 0.494±0.14 Uniform, no crystallization 10 Yellow-green uniform gel 9.79±0.06 7.01±0.13 0.503±0.41 Uniform, no crystallization
[0047] The above results show that the addition of 10% tea tree oil has no significant effect on the brimonidine content, pH and appearance of the gel, indicating that the tea tree oil and brimonidine in the gel have good compatibility.
[0048] Example 10 Pharmacodynamic Evaluation of Gel
[0049] (1) Establishment and treatment of LL-37 antimicrobial peptide-induced rosacea model in mice
[0050] Mice were first raised in an independent ventilation cage for 48h to reduce stress response. The hair on the back of mice was shaved with a razor 24h before the experiment. Mice were randomly divided into A (blank control group), B (modeling group), C (low-concentration tea tree oil gel group in embodiment 5), D (medium-concentration tea tree oil gel group in embodiment 5), E (high-concentration tea tree oil gel group in embodiment 5), F (brimonidine gel group in embodiment 3), G (brimonidine gel group of low-concentration tea tree oil in embodiment 4), H (brimonidine gel group of medium-concentration tea tree oil in embodiment 4), I (brimonidine gel group of high-concentration tea tree oil in embodiment 4), 6 in each group.
[0051] A circular area with a diameter of 1 cm was selected from the central part of the back of the mouse as the test site. Every 12 hours, 50 μl of LL-37 solution was subcutaneously injected into the test area on the back of the mice in groups B, C, D, E, F, G, H, and I until dermal blebs and erythema were formed. This was performed 6 times in total. Group A was subcutaneously injected with water for injection for preparing LL-37 solution at the same location and frequency. After the third injection of LL-37, groups C, D, E, F, G, H, and I were treated with 0.5 g of gel sample each, twice a day, for 3 consecutive days.
[0052] (2) Results
[0053] The affected area was photographed with a camera before the first gel treatment and 24 h after the last gel administration, and the total area of erythema in the affected area of each experimental mouse was measured using imageJ software, and the reduction in erythema area was calculated. The results are shown in Tables 2 and Figure 4 .
[0054] At the same time, 24 hours after the last drug administration, the skin damage score of the rosacea erythema in the test area of the mice was scored. Referring to the clinical scoring table of dermatological diseases, the degree of skin damage, the degree of erythema spread, the edema and pustule conditions and other indicators were used to quantitatively analyze the rosacea symptoms of each experimental subject according to 1-5 points (5 points are the highest). The efficacy score was calculated according to the efficacy score = erythema area reduction / (0.2*erythema spread score+0.4*skin damage score+0.4*edema and pustule score). The larger the score value, the better the treatment effect. The results are shown in Table 2 and Figure 5 .
[0055] Table 2 Comparison of erythema area before and after gel treatment
[0056]
[0057] # Compared with group B data, P < 0.05, ## Compared with group B data, P < 0.01; *Compared with group F data, P < 0.05, **Compared with group F data
[0058] Comparison P < 0.01; ☆ Compared with the data of group G, P < 0.05, ☆☆ Compared with the data of group G, P<0.01.
[0059] Table 2 and Figure 4The results showed that before treatment, all groups except the control group (group A) formed obvious rosacea-like erythema, indicating that the model was successfully established. At 24 hours after the last administration of the drug, the area of rosacea-like erythema in the affected part of the mice in each administration group (groups C to I) was reduced. From the Δ value of the reduction in the area of erythema, the Δ value of each administration group (group CI) was significantly increased compared with the Δ value of group B (modeling group) (P < 0.01), indicating that tea tree oil gel, brimonidine tartrate gel and brimonidine tartrate gel containing tea tree oil can significantly reduce the area of erythema in the test part of the mice. Compared with the Δ value of group F (brimonidine gel group), although the Δ values of the three groups of tea tree oil gel (groups C, D, and E) increased to a certain extent and showed dose-effect dependence, only the Δ value of the high-dose tea tree oil gel group (group E) was statistically significant compared with the Δ value of group F (P < 0.05); it is interesting that the Δ values of the three groups of brimonidine gel containing tea tree oil (groups G, H, and I) increased significantly compared with the Δ value of group F, among which the Δ values of groups H and I were extremely significantly different from the Δ value of group F (P < 0.01), but the Δ values of groups H and I were similar, and there was no significant difference between the two (P > 0.05), indicating that when the addition amount of tea tree oil reaches 10% or more, tea tree oil-brimonidine tartrate gel has the best effect on reducing the area of erythema.
[0060] From the efficacy score data (see Table 2 and Figure 5 ), the efficacy scores of the drug-treated groups (CI group) were significantly improved compared with those of group B (modeling group) (P<0.01), indicating that tea tree oil gel, brimonidine gel and brimonidine gel containing tea tree oil can effectively alleviate the overall symptoms of the tested parts of mice. The efficacy scores of groups D and E were better than those of group F (P<0.01), indicating that tea tree oil alone is better than brimonidine in treating skin lesions, edema, pustules and other symptoms. Groups H and I had the largest efficacy data and the best therapeutic effect, and the difference was extremely significant compared with group F (P<0.01). Groups H and I not only significantly reduced the area of erythema, but also more significantly alleviated the symptoms, and the lesions were basically healed. The efficacy was significantly better than brimonidine gel, indicating that the addition of tea tree oil can significantly improve the efficacy of brimonidine on common symptoms of rosacea such as erythema, lesions, edema, and pustules.
[0061] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. Therefore, all equivalent changes and modifications made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
Claims
1. A novel topical brimonidine gel, characterized in that The invention relates to a composition comprising the following substances in a weight ratio: 0.03-6.6% (w / w) brimonidine tartrate, 10-30% (w / w) volatile oil, 1-2% (w / w) gelling agent, 4.5-15% (w / w) moisturizing agent, 0.05-0.5% (w / w) physical sunscreen agent, 0.5-2.5% (w / w) pH adjusting agent, and an appropriate amount of pure water; the pH value of the gelling agent is 5.5-8.0; wherein the volatile oil is tea tree oil; the gelling agent is carbomer 974P; the moisturizing agent is propylene glycol and glycerol; the physical sunscreen agent is titanium dioxide; The pH regulator is sodium hydroxide; the novel topical brimonidine gel is prepared by the following method: accurately weighing a prescribed amount of gelling agent, adding an appropriate amount of pure water, swelling for 12 hours for standby use, accurately weighing a prescribed amount of brimonidine tartrate, volatile oil, moisturizer, and physical sunscreen, adding them to the swollen carbomer solution, stirring at 500 r / min for 15 minutes until the mixture is completely mixed, then increasing the speed to 800 r / min, adjusting the pH with a 1.5M sodium hydroxide solution, finally adding an appropriate amount of pure water to a sufficient amount, and continuously stirring until the finished product is a light yellow-green uniform gel.
2. Use of the novel topical brimonidine gel according to claim 1 in the preparation of a medicament for treating mild and moderate erythematous vasodilation and papulopustular rosacea.
Citation Information
Cited By
External gel preparation and preparation method thereof
CN120078706A
